Skip to content

Released Aug 5, 2025, before the open

10-Q filed Aug 5, 2025, 37 days after period end · 0000078003-25-000138

Q2 2025 · 10-Q
Revenue$14.65B+10.3% vs Q2 2024+6.8% vs Q1 2025
Net Income$2.91B+6,997.6% vs Q2 2024−1.9% vs Q1 2025
EPS Diluted$0.51+5,000.0% vs Q2 2024−1.9% vs Q1 2025
Operating Cash Flowderived-$582,000,000N/M
Free Cash Flowderived-$1,200,000,000N/M
Margins · derived
Net margin19.9%+19.6 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$14.65B$13.28B$13.01B$27.74B
Net Income$2.91B$41.00M$2.33B$9.91B
EPS Diluted$0.51$0.01$0.41$1.73

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR